You are here

  • Home
  • Archive
  • Volume 7, Issue 6
  • Galantamine improved cognition and global functioning in vascular dementia or Alzheimer’s disease with cerebrovascular disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Galantamine improved cognition and global functioning in vascular dementia or Alzheimer’s disease with cerebrovascular disease

https://doi.org/10.1136/ebm.7.6.179

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 359, 1283; Erkinjuntti T, Kurz A, Gauthier S, et al.. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial.. Apr 13;. :. –90.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with probable vascular dementia or Alzheimer’s disease (AD) with cerebrovascular disease, is galantamine more effective than placebo for improving cognitive ability and global functioning?

    Design

    6 month randomised (unclear allocation concealment*), blinded (clinicians and patients),* placebo-controlled trial.

    Setting

    Canada, Denmark, Finland, France, Germany, Ireland, Israel, The Netherlands, Poland, and the UK.

    Patients

    592 patients (mean age 75 y, 53% men) who met clinical criteria for probable vascular dementia or possible AD with radiological evidence of cerebrovascular disease. Additional inclusion criteria included a score of 10 to 25 on the Mini-Mental State Examination and ≥12 on the Alzheimer Disease Assessment Scale Cognitive subscale (ADAS-COG). Exclusion criteria included evidence of neurodegenerative disorders other than AD that might cause or contribute to dementia, and cognitive …

    View Full Text

    Footnotes

    • Source of funding: not stated.

    • For correspondence: Dr T Erkinjuntti, Helsinki University Central Hospital, Helsinki, Finland. Email timo.erkinjuntti{at}hus.fi.

    • * See glossary.